[{"id":"d9c9428c-3a59-4384-ad4e-5e3646ac2fde","acronym":"TAVO412","url":"https://clinicaltrials.gov/study/NCT05548634","created_at":"2022-09-21T18:56:21.079Z","updated_at":"2024-07-02T16:35:26.126Z","phase":"Phase 1","brief_title":"A Study of TAVO412 in Patients With Cancer","source_id_and_acronym":"NCT05548634 - TAVO412","lead_sponsor":"Tavotek Biotherapeutics","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MP412 • TAVO412"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-15"}]